[Level of Soluble Receptor for Glycation End-Products in Patients With Restenosis After Coronary Artery Stenting].

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Kardiologiia

• Publication date

  2016-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.18565/CARDIO.2016.4.5-10PMID 28294852
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Usefulness of preprocedural levels of advanced glycation end products to predict restenosis in patients with controlled diabetes mellitus undergoing drug-eluting stent implantation for stable angina pectoris (from the Prospective ARMYDA-AGEs Study).

  2013cited by this paper
• The N-glycoform of sRAGE is the key determinant for its therapeutic efficacy to attenuate injury-elicited arterial inflammation and neointimal growth

  2013cited by this paper
• Serum advanced glycation end-products and receptors as prognostic biomarkers in diabetics undergoing coronary artery stent implantation.

  2012cited by this paper
• Enhanced expression of receptor for advanced glycation end-products is associated with low circulating soluble isoforms of the receptor in Type 2 diabetes.

  2011cited by this paper
• Soluble receptor for advanced glycation end products is associated with in-stent restenosis in patients with type 2 diabetes with drug-eluting coronary stents

  2011cited by this paper
• Soluble Receptors for Advanced Glycation End Products (sRAGE) as a Predictor of Restenosis Following Percutaneous Coronary Intervention

  2010cited by this paper
• RAGE: a novel biological and genetic marker for vascular disease.

  2009cited by this paper
• Receptor for Advanced Glycation End Products Is Subjected to Protein Ectodomain Shedding by Metalloproteinases*

  2008cited by this paper
• Increased glycated albumin and decreased esRAGE concentrations are associated with in-stent restenosis in Chinese diabetic patients.

  2008cited by this paper
• A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane‐bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10)

  2008cited by this paper
• Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease

  2007cited by this paper
• Receptor for AGE (RAGE) Mediates Neointimal Formation in Response to Arterial Injury

  2003cited by this paper
• Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury.

  2003cited by this paper
• Central role of RAGE-dependent neointimal expansion in arterial restenosis.

  2003cited by this paper
• Tissue-specific expression patterns of the RAGE receptor and its soluble forms--a result of regulated alternative splicing?

  2003cited by this paper
• RAGE‐mediated neutrophil dysfunction is evoked by advanced glycation end products (AGEs)

  2002cited by this paper
• Glycation Products and the Pathogenesis of Diabetic Complications

  1992cited by this paper

• No citing papers are available for this paper.